ataluren
Sign in to saveAlso known as PTC124, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid, EC-000.2051
Ataluren, sold under the brand name Translarna, is a medication for the treatment of Duchenne muscular dystrophy. It was designed by PTC Therapeutics.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.image
- Ataluren.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Ataluren ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Translarna
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- M09
- Drug.ATC_suffix
- AX03
- Drug.legal_UK
- POM
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 775304-57-9
- Drug.PubChem
- 11219835
- Drug.IUPHAR_ligand
- 7341
- Drug.DrugBank
- DB05016
- Drug.ChemSpiderID
- 9394889
- Drug.UNII
- K16AME9I3V
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 284.05972
- Has use
- medication
Show 5 more facts
- chemical formula
- C₁₅H₉FN₂O₃
- World Health Organisation international non-proprietary name
- 阿他卢仑
- canonical SMILES
- C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F
- medical condition treated
- Duchenne muscular dystrophy
- Commons category
- Ataluren
via Wikidata · CC0
~6 min read
Encyclopedic overview
10 sectionsContents
- Medical use
- Contraindications
- Adverse effects
- Interactions
- Pharmacology
- Chemistry
- History
- Society and culture
- Legal status
- References
Ataluren, sold under the brand name Translarna, is a medication for the treatment of Duchenne muscular dystrophy. It was designed by PTC Therapeutics.
==Medical use== Ataluren is used in the European Union to treat people with Duchenne muscular dystrophy who have a nonsense mutation in the dystrophin gene, can walk, and are more than five years old.
Excerpted from Wikipedia’s “ataluren” article, available under the CC BY-SA 4.0 licence.